PLoS ONE (Jan 2021)

Evoked potentials as biomarkers of hereditary spastic paraplegias: A case-control study.

  • Samanta Ferraresi Brighente,
  • Paul Vicuña,
  • Ana Luiza Rodrigues Louzada,
  • Gabriela Marchisio Giordani,
  • Helena Fussiger,
  • Marco Antonnio Rocha Dos Santos,
  • Diana Maria Cubillos-Arcila,
  • Pablo Brea Winckler,
  • Jonas Alex Morales Saute

DOI
https://doi.org/10.1371/journal.pone.0259397
Journal volume & issue
Vol. 16, no. 11
p. e0259397

Abstract

Read online

IntroductionThe Hereditary Spastic Paraplegias (HSP) are a group of genetic diseases that lead to slow deterioration of locomotion. Clinical scales seem to have low sensitivity in detecting disease progression, making the search for additional biomarkers a paramount task. This study aims to evaluate the role of evoked potentials (EPs) as disease biomarkers of HSPs.MethodsA single center cross-sectional case-control study was performed, in which 18 individuals with genetic diagnosis of HSP and 21 healthy controls were evaluated. Motor evoked potentials (MEP) obtained with transcranial magnetic stimulation and somatosensory evoked potentials (SSEP) were performed in lower (LL) and upper limbs (UL).ResultsCentral motor conduction time in lower limbs (CMCT-LL) was prolonged in HSP subjects, with marked reductions in MEP-LL amplitudes when compared to the control group (pConclusionMotor and somatosensory evoked potentials can adequately differentiate HSP individuals from controls. MEP were severely affected in HSP subjects and SSEP-LL latencies were prolonged, with longer latencies being related to more severe disease. Future longitudinal studies should address if SSEP is a sensitive disease progression biomarker for HSP.